Temozolomide in grade III neuroendocrine neoplasms (G3 NENs): A multicenter retrospective review.

Abstract

321Background: G3 NENs are aggressive, and optimal systemic treatment is unclear. Temozolomide (TEM)-based regimens have been used to treat grade 1-2 NETs, but their efficacy in G3 NENs (Ki-67 > 20...